Inhibitors as a therapeutic frontier in lung cancer: Mechanism, opportunities, and molecular docking studies

Lung cancer remains one of the leading causes of death worldwide, and novel therapies are urgently needed to enhance patient outcomes. Recent advancements have highlighted the potential of molecular inhibitors that target specific signaling pathways, offering promising treatment alternatives. These inhibitors block key pathways such as EGFR, ALK, and ROS1, which are often dysregulated in lung cancer and play essential roles in cell proliferation, apoptosis, and metastasis. By selectively targeting these pathways, inhibitors may reduce adverse effects, improve therapeutic efficacy, and minimize damage to healthy cells. This paper explores how these inhibitors affect lung cancer cells, examining recent developments and emerging opportunities. It also discusses the role of molecular docking studies, which are crucial in drug development as they reveal the molecular interactions and binding affinities between inhibitors and their target proteins. Molecular docking has significantly advanced the design of inhibitors, enhancing their potency and specificity for clinical use. By analyzing these computational models, this study evaluates molecular inhibitors' real-world applications and future potential in lung cancer treatment. The findings emphasize the importance of targeted approaches, highlighting the challenges and successes in developing molecular inhibitors and paving the way toward precision medicine.